

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

10.05.2017

**BSE Limited** Department of Corporate Relationship 1st Floor, New Trade Ring, Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001

Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd., Department of Corporate Services Exchange Plaza, 5<sup>th</sup> Floor, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: CAPLIPOINT.

**By NEAPS** 

Dear Sirs,

SUB :PRESS RELEASE - DISCLOSURE UNDER REGULATION 30 OF SEBI ( LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find the enclosed copy of press release with respect to Audited Financial results for the quarter and year ended March 31,2017 being released today.

Thanking You,

Yours Faithfully, For Caplin Point Laboratories Limited

Company Secretary **Enclosure: As Above** 



Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

### PRESS RELEASE

# Revenue growth at 30%; PAT up 64%

Results - Q4 FY 17 and FY 2017

Chennai, May 10, 2017: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) today reported its financial results for the Quarter (Q4 FY 17) and financial year ended March 31, 2017.

### Key Financial & Performance Highlights - Consolidated

**INR Lacs** 

Details	Q4 FY17	Q4 FY 16	Growth %	FY17	FY 16 (12months)*	Growth (Annualised)
Gross Revenue	12052	8191	47%	40510	31342	30%
EBITDA	4764	2210	116%	13521	8733	55%
EBITDA %	40%	27%		33%	28%	**
PAT	3341	1558	114%	9616	5848	64%
PAT %	28%	19%		24%	19%	

### Key Financial & Performance Highlights - Standalone

Details	Q4 FY 17	Q4 FY 16	Growth %	FY 17	FY 16 (12months)*	Growth (Annualised)
Gross Revenue	9624	7864	22%	34772	30316	17%
EBITDA	3519	2119	66%	10680	8515	25%
EBITDA %	37%	27%		31%	28%	
PAT	2190	1515	43%	7086	5802	22%
PAT %	23%	19%		20%	19%	

<sup>\*</sup>Annualised by taking into consideration the quarterly results for the period April 2015 to March 2016.

Some of the key highlights of performance for the last year are captured below:

### Financial (consolidated)

- ✓ Top line crossing INR 400cr mark 30% growth over previous year
- ✓ Increase in Contribution Margin by INR 70cr growth of 45% higher than top line growth.
- ✓ Contribution % increased from 50 to 55%.
- ✓ Opex increase only by INR 25cr. Opex as a % of Revenue decreased by 1 % (26 to 25) despite quantum increase of INR 25cr.
- ✓ PBT grew by INR 45cr (76 to 121) 60% growth over previous year.





Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653. 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

- ✓ PAT @ INR 96cr 64% growth over previous year.
- ✓ EPS grew by 57% from INR 8.07 (annualised) to INR 12.72
- ✓ Company pays Tax under MAT.
- ✓ Company invested close to INR 27cr in Fixed Assets. Thrust on R & D INR 16cr.
- ✓ R & D spend at 31% of PAT, as compared to 19% in the previous 12 months.
- ✓ ROCE at 70% (up from 69%)
- ✓ Debt-free Company (having Cash & Cash equivalents of INR 91cr, up from 67cr the previous year).
- ✓ More than 2/3<sup>rd</sup> of Reserves & Surplus is available in Cash, Bank and Other Liquid Assets.
- ✓ Current asset management :
  - Less than 45 days consumption as inventory
    - Trade receivables INR 33cr represents part of last month's sales

### Non-Financial

- ✓ US FDA approval received for Injectable site at Chennai (CP-4).
- ✓ 2 ANDAs filed, with 7 more in the pipeline to be filed before Dec 2017.
- ✓ Plant is also approved by EUGMP, ANVISA-Brazil & INVIMA-Colombia.
- ✓ Added another 300 new product registrations in the 12 months ended Mar 17
- ✓ Total tally of active registrations as on date over 2300.
- ✓ Approval for 350 more products in pipeline, expected in the next 12 months.
- ✓ Expected entry into Colombia, Chile and Paraguay in the next 12 months.
- ✓ R & D strength increased by over 30%.
- ✓ Capex plans in place for next Injectable plant for ROW markets in Puducherry.

## <u>About Caplin Point Laboratories Limited:</u>

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company currently holds over 2300 product licenses across Latin America and Africa with another 350 in the pipeline.

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), one of the very few companies to appear on the list for three successive years.





Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653. 28156905 Fax +91 44 28154952 E-mail info@caplinpoint.net Website www.caplinpoint.net

#### **Cautionary Statement:**

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

